86th Congress of the European Atherosclerosis Society 2018
VIDEO: What’s in the PCSK9 pipeline?
PCSK9 antibody therapy is indisputably effective, well tolerated and improves clinical outcomes; however, cost is an issue. PCSK9 Forum Editor Professor Derick Raal (University of Witwatersrand, Johnannesburg, South Africa) discusses what to look forward to after the PCSK9 monoclonal antibodies.
read more »
Low LDL cholesterol due to PCSK9 variants reduces mortality
A Mendelian randomization study in more than 100,000 Danish individuals showed that PCSK9 variants linked with low LDL cholesterol levels were associated with reduced cardiovascular and all-cause mortality. These findings were reported during the 86th Annual Congress of the European Atherosclerosis Society (EAS) in Lisbon,…
read more »
Real-world use of PCSK9 inhibitors
Real-world data on the use of PCSK9 inhibitors in Belgium, Germany and Austria and the UK show that these agents are as effective and well tolerated as reported in clinical trials. These findings were reported during the 86th Annual Congress of the European Atherosclerosis Society…
read more »
First data from the Homozygous Familial Hypercholesterolaemia International Clinical Collaborators (HICC) Registry
These preliminary data from the largest cohort to date in patients with homozygous familial hypercholesterolaemia (FH), the most severe form of this inherited condition, has reaffirmed the high cardiovascular risk of these patients. These findings were reported during the 86th Annual Congress of the European…
read more »
EPIC-Norfolk Study: No effect on cognition of long-term exposure to low LDL cholesterol levels
Adding to the conclusions of the European Atherosclerosis Society (EAS) Consensus Panel,1 a new analysis from the European Prospective Investigation of Cancer (EPIC)-Norfolk prospective population study has provided further reassurance about the safety of long-term low LDL cholesterol levels on cognition. The results of this…
read more »
EAS Consensus Panel: Statins do not impair cognitive function
EAS Panel Co-Chair discusses the evidence-based conclusions from this latest EAS Consensus Panel statement on adverse effects of statin therapy, focusing on effects on cognitive function.
read more »
EAS Congress: FOURIER analysis shows benefit of PCSK9 inhibition in patients with elevated lipoprotein(a)
Dr Michelle O’Donogue (Brigham and Women’s Hospital, Boston, USA) discusses the key findings from this FOURIER analysis and what it means for patients
read more »
More Late Breaker News: ORION-1 and EUROASPIRE V
In the ORION-1 study, treatment with the PCSK9 inhibitor inclisiran led to substantial reductions in other atherogenic lipoproteins, specifically non-high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo) B and lipoprotein(a). The magnitude of change was broadly similar to that reported with PCSK9 monoclonal antibody therapy. Results were…
read more »
How much lipoprotein(a) lowering is required for cardiovascular benefit?
A genetics analysis suggests that lipoprotein(a) mass needs to be lowered by at least 100 mg/dl for a clinically meaningful reduction in coronary heart disease (CHD) risk. The study was reported during the 86th Annual Congress of the European Atherosclerosis Society (EAS) in Lisbon, Portugal….
read more »
FOURIER looks at impact of baseline lipoprotein(a)
In the FOURIER trial, patients with the highest levels of lipoprotein(a) and highest LDL cholesterol levels obtained the greatest clinical outcomes benefit from PCSK9 inhibition. The results of this analysis from the FOURIER study with evolocumab were reported during the 86th Annual Congress of the…
read more »
